An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.
A61F 6/14 - Contraceptive devicesPessariesApplicators therefor for use by females intra-uterine type
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 9/00 - Medicinal preparations characterised by special physical form
A61F 6/08 - Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
2.
Drug delivery system for one or more active ingredients
A drug delivery system that includes an elongated inert support and at least two reservoirs containing a pharmaceutically active ingredient. The inert support has a number of wall segments that define at least two compartments arranged for accommodating the at least two reservoirs. The inert support is made of a material which prevents migration or diffusion of the active ingredient from one reservoir into the other or into the support. Since the drug delivery system is divided into compartments, one for each reservoir containing an active ingredient, the release rates of each active ingredient can be independently controlled or adjusted. This is due to the fact that there is no interaction between the active ingredients, and accordingly the active ingredients will not influence each other physically or chemically.
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61F 6/08 - Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception
A61F 6/14 - Contraceptive devicesPessariesApplicators therefor for use by females intra-uterine type
3.
AN INSERTABLE MOULD ASSEMBLY, A SUBSTRATE AND AN INJECTION MOULDING TOOL FOR THE INSERTABLE MOULD ASSEMBLY, METHOD OF USING THE INSERTABLE MOULD ASSEMBLY AND THE INJECTION MOULDING TOOL, OBJECTS OBTAINED USING SAME, AND USES OF THE OBJECTS
An insertable mould assembly (1) for an injection moulding machine comprises a first mould part (2) and a second mould part (3) alignable with the first mould part (2). At least one overmould cavity (23a,23b,23c,23d,23e,23f,23g,23h) is delimited between the first mould cavity face (12) and the second mould cavity face (13) in a closed condition of the insertable mould assembly (1). The at least one overmould cavity (23a,23b,23c,23d,23e,23f,23g,23h) is configured and dimensioned to receive at least a part of a substrate (10) of a first component material, which substrate (10) has been premade in another, separate process. In a method of using the insertable mould assembly IUDs are overmoulded with medicament reservoirs to obtain IUDs with rounded corners and edges.
B29C 45/14 - Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mouldApparatus therefor incorporating preformed parts or layers, e.g. injection moulding around inserts or for coating articles
B29K 83/00 - Use of polymers having silicon, with or without sulfur, nitrogen, oxygen or carbon only, in the main chain, as moulding material
B29C 45/64 - Mould opening, closing or clamping devices
4.
Intrauterine device and method for reducing the rate of diffusion of active ingredients in said device by adding inert particulates to a polymeric coating
An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.
A61F 6/14 - Contraceptive devicesPessariesApplicators therefor for use by females intra-uterine type
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 9/00 - Medicinal preparations characterised by special physical form
A61F 6/08 - Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
5.
A DRUG DELIVERY SYSTEM FOR ONE OR MORE ACTIVE INGREDIENTS
A drug delivery system (1) comprise an elongated inert support (2) and at least two reservoirs (3,8,12,14,17,19,21,23,29) comprising a pharmaceutically active ingredient. Said inert support (2) comprises a number of wall segments (4), defining at least two compartments (5) along said support (2), said compartments are arranged for accommodating the at least two reservoirs. The inert support (2) is made of a material, which prevents migration and/or diffusion of active ingredient from one reservoir into the support (2) and further into at least one neighbouring reservoir. Since the drug delivery system (1) is divided into compartments (5), one for each reservoir containing an active ingredient, the release rates of each active ingredient can be independently controlled and/or adjusted. This is due to the fact that there is no interaction between the active ingredients, and accordingly said active ingredients will not influence each other physically or chemically.
An intrauterine device (1,1', 1") comprising at least one first pharmaceutically active ingredient (5) and at least one first layer (4) made of at least a first polymeric material, and wherein between about 10 and about 60 v/v% of at least one particulate material (6) is dispersed and/or incorporated in said first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstructs the diffusion of the pharmaceutically active ingredient being released, thereby slowing the rate of release of the pharmaceutically active ingredient. In this way, it is possible to regulate the release rate and/or initial burst of the IUD, by adjusting the amount of particles/particulate material in the first layer, instead of as conventional having to adapt the size of the IUD to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.
patents
